TheraRadar
Data updated: May 26, 2026

ROLVEDON (eflapegrastim-xnst)

Oncology Approved 2022-09-09

Rolvedon (eflapegrastim-xnst) is a leukocyte growth factor indicated to decrease the incidence of infection, as manifested by febrile neutropenia, in adult patients. It is used for individuals with non-myeloid malignancies who are receiving myelosuppressive anti-cancer drugs associated with a clinically significant risk of febrile neutropenia. The therapy is not indicated for the mobilization of peripheral blood progenitor cells for hematopoietic stem cell transplantation.

Source: FDA Label • SPECTRUM PHARMS • Leukocyte Growth Factor

How ROLVEDON Works

Eflapegrastim-xnst is a recombinant human granulocyte growth factor that binds to G-CSF receptors on myeloid progenitor cells and neutrophils. This binding triggers specific signaling pathways that control the differentiation, proliferation, migration, and survival of these cells. By activating these pathways, the drug promotes the development and maintenance of the immune cells necessary to prevent infection.

1
Indication
--
Phase 3 Trials
3
Years on Market

Details

Status
Prescription
First Approved
2022-09-09
Routes
SUBCUTANEOUS
Dosage Forms
INJECTABLE

Companies

Active Ingredient: EFLAPEGRASTIM-XNST

ROLVEDON Approval History

2023
2024
2025
2026
Original
New Indication
New Form
Label Update
3 FDA actions from 2022 to 2025
Dec 2025 SUPPL
Label · Labeling
Jun 2023 SUPPL
Label · Labeling
Sep 2022 ORIGINAL
New Drug · Type 1 - New Molecular Entity

What ROLVEDON Treats

2 indications

ROLVEDON is approved for 2 conditions since its original approval in 2022. These indications span multiple therapeutic areas including oncology, immunology, and more.

  • Febrile Neutropenia
  • Infection
Source: FDA Label

ROLVEDON Competitive Set

Pro

Three rings of competition based on shared molecular targets and treated indications.

Unlock 8 more competitors across all three rings.
Upgrade to Pro

Filters applied: drops same-active-ingredient (505(b)(2) reformulations), route-mismatch (topical vs systemic), and cross-therapeutic-area matches in same-indication rings.

Drugs Similar to ROLVEDON

3 of 20

FDA-approved drugs for similar conditions. Compare mechanisms and indications to understand treatment alternatives.

NYVEPRIA
PEGFILGRASTIM-APGF
2 shared
Pfizer
Shared indications:
ARMLUPEG
PEGFILGRASTIM-UNNE
1 shared
Lupin
Shared indications:
CEFEPIME AND DEXTROSE IN DUPLEX CONTAINER
CEFEPIME HYDROCHLORIDE
1 shared
B BRAUN
Shared indications:
🔬

Active Pipeline

Pro

Ongoing clinical trials by development phase

Loading...

Key Completed Trials

Pro

Completed studies with published results, ranked by significance

Loading...
📊

Trial Timeline

Full development history with FDA approval milestones

|
Loading...
Understanding FDA Approval Types
Count Type What it means
- ORIG Original approval - drug first enters market
- SUPPL - Efficacy New indication (new disease/condition approved)
- SUPPL - Labeling Label text changes (warnings, dosing updates)
- SUPPL - Manufacturing Production changes (new facility)
- SUPPL - Chemistry Formulation changes (new dosage strength)

Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.

ROLVEDON FDA Label Details

Indications & Usage

FDA Label (PDF)

ROLVEDON is indicated for the treatment of Febrile Neutropenia; Infection.

Track ROLVEDON with TheraRadar Pro

Watchlist alerts, full database access, CSV exports across 14,000+ drugs.

Upgrade to Pro

Data Sources

Data sourced from official FDA and NIH databases. Click links to verify on original sources.